Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald

Paratek Pharmaceuticals (NASDAQ:PRTK) has been given a $50.00 target price by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 283.14% from the stock’s previous close.

A number of other research firms also recently issued reports on PRTK. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. HC Wainwright lifted their price target on shares of Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, January 23rd. UBS downgraded shares of Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Friday, March 2nd. Finally, Leerink Swann reiterated an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Sunday, March 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $40.00.

How to Become a New Pot Stock Millionaire

Shares of PRTK opened at $13.05 on Thursday. Paratek Pharmaceuticals has a twelve month low of $11.85 and a twelve month high of $29.00. The company has a market capitalization of $418.19, a price-to-earnings ratio of -3.95 and a beta of 0.43. The company has a debt-to-equity ratio of 0.72, a quick ratio of 9.56 and a current ratio of 9.56.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative net margin of 706.00% and a negative return on equity of 93.16%. The business had revenue of $5.07 million during the quarter, compared to analysts’ expectations of $5.00 million. analysts expect that Paratek Pharmaceuticals will post -3.44 EPS for the current year.

In related news, Chairman Michael Bigham sold 4,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $56,880.00. Following the completion of the transaction, the chairman now directly owns 123,680 shares in the company, valued at approximately $1,758,729.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Radie sold 3,000 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total value of $42,660.00. Following the transaction, the director now owns 9,330 shares of the company’s stock, valued at $132,672.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,664 shares of company stock valued at $573,226. Insiders own 4.90% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH raised its position in shares of Paratek Pharmaceuticals by 6.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 65,366 shares of the specialty pharmaceutical company’s stock worth $1,641,000 after purchasing an additional 3,719 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth approximately $104,000. SG Americas Securities LLC acquired a new position in shares of Paratek Pharmaceuticals during the 3rd quarter worth approximately $123,000. LPL Financial LLC raised its position in shares of Paratek Pharmaceuticals by 13.0% during the 4th quarter. LPL Financial LLC now owns 44,575 shares of the specialty pharmaceutical company’s stock worth $798,000 after purchasing an additional 5,125 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Paratek Pharmaceuticals by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 200,782 shares of the specialty pharmaceutical company’s stock worth $3,593,000 after purchasing an additional 5,151 shares during the last quarter. Hedge funds and other institutional investors own 74.44% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3336851/paratek-pharmaceuticals-prtk-pt-set-at-50-00-by-cantor-fitzgerald.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Energy Fuels  Director Dennis Lyle Higgs Sells 10,000 Shares of Stock
Energy Fuels Director Dennis Lyle Higgs Sells 10,000 Shares of Stock
TSE Technischer Service und Equipment – Hasenschwandtner Peter  Insider Nathan Mekuz Purchases 40,000 Shares
TSE Technischer Service und Equipment – Hasenschwandtner Peter Insider Nathan Mekuz Purchases 40,000 Shares
Commerce Bancshares  VP Daniel D. Callahan Sells 1,057 Shares
Commerce Bancshares VP Daniel D. Callahan Sells 1,057 Shares
Tupperware Brands  VP Lillian D. Garcia Acquires 2,320 Shares
Tupperware Brands VP Lillian D. Garcia Acquires 2,320 Shares
CompuCoin  Price Up 17.3% This Week
CompuCoin Price Up 17.3% This Week
U.CASH Price Tops $0.0037
U.CASH Price Tops $0.0037


Leave a Reply

© 2006-2018 Ticker Report. Google+.